VISTIDE (nda020638)- (EQ 75MG BASE/ML)

Generic Name	CIDOFOVIR	Innovator	GILEAD SCIENCES INC
Dosage	EQ 75MG BASE/ML
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2010-Jun-26	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Vistide is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
2	0	2

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 75MG BASE/ML	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	2

Manufacturing Details of VISTIDE